{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:22:06Z","timestamp":1789032126621,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Oxford NIHR Biomedical Research Centre"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Venetoclax is a<jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>2 inhibitor with activity in relapsed\/refractory (R\/R) chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>). We conducted a multi\u2010centre retrospective analysis of 105 R\/R<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>patients who received venetoclax pre\u2010National Health Service commissioning. The median age was 67\u00a0years and median prior lines was 3 (range: 1\u201315). 48% had<jats:italic><jats:styled-content style=\"fixed-case\">TP<\/jats:styled-content>53<\/jats:italic>disruption. At \u22652 lines, 60% received a Bruton Tyrosine Kinase inhibitor (<jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content>i) and no prior phosphoinositide 3\u2010kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no prior<jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content>i, and 10% received both. Patients discontinued B cell receptor inhibitor (<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>i) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>]). The overall response rate was 85% (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>23%) in<jats:styled-content style=\"fixed-case\">BTK<\/jats:styled-content>i\u2010exposed patients, 92% (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>38%) in Pi3Ki\u2010exposed patients and 80% (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>20%) in both (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b759). With a median follow\u2010up of 15\u00b76\u00a0months, 1\u2010year progression\u2010free survival was 65\u00b70% and 1\u2010year overall survival was 75\u00b71%. Dose reduction or temporary interruption did not result in an inferior progression\u2010free or discontinuation\u2010free survival. Risk of progression or death after stopping a prior<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>i for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2\u00b701<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b705). Venetoclax is active and well tolerated in R\/R<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>post \u22651<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>i. Reason(s) for stopping<jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>i influences venetoclax outcomes.<\/jats:p>","DOI":"10.1111\/bjh.15802","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T12:04:57Z","timestamp":1550232297000},"page":"656-669","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post\u2010<scp>BCR<\/scp>inhibitor setting: a<scp>UK<\/scp>wide analysis"],"prefix":"10.1111","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"first","affiliation":[{"name":"Department of Haematology Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Cancer Research UK &amp; UCL Cancer Trials Centre UCL London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sat","family":"Gohill","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospitals London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Follows","sequence":"additional","affiliation":[{"name":"Department of Haematology Addenbrooke's Hospital NHS Trust Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Walewska","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Bournemouth Hospital Bournemouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Haematology Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cross","sequence":"additional","affiliation":[{"name":"Department of Haematology The Royal Marsden Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Forconi","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospital Trust and Cancer Sciences Unit Cancer Research UK and National Institute for Health Research Experimental Cancer Medicine Centres Faculty of Medicine University of Southampton Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Haematology Norfolk and Norwich University Hospital National Health Service Trust Norwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chasty","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals of North Midlands NHS Trust Stoke\u2010on\u2010Trent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Haematology Queen Elizabeth University Hospital Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Broom","sequence":"additional","affiliation":[{"name":"Department of Haematology Western General Hospital Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marr","sequence":"additional","affiliation":[{"name":"Department of Haematology Freeman Hospital Newcastle on Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers E. M.","family":"Patten","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine Kings College Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Dann","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010Oncology The Ipswich Hospital NHS Trust Ipswich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Arumainathan","sequence":"additional","affiliation":[{"name":"Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Munir","sequence":"additional","affiliation":[{"name":"Department of Haematology St James's University Hospital Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paneesha","family":"Shankara","sequence":"additional","affiliation":[{"name":"Department of Haematology Heartlands Hospital Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[{"name":"Department of Haematology The Christie Hospital NHS Trust Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalynd","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Sussex County Hospital Brighton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Orchard","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation University Hospital Southampton Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna H.","family":"Schuh","sequence":"additional","affiliation":[{"name":"Department of Haematology Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford UK"},{"name":"Oxford Molecular Diagnostic Centre Department of Oncology University of Oxford John Radcliffe Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Haematology Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the UK CLL Forum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788133"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Models and life\u2010tables regression","volume":"34","author":"Cox D.R.","year":"1972","journal-title":"Journal of the Royal Statistics Society"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3761"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_8_9_1","first-page":"428","article-title":"Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6\u00a0months of combination therapy","volume":"130","author":"Hillmen P.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_2_8_11_1","first-page":"65","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open\u2010label, phase 2 trial","volume":"1","author":"Jones J.A.","year":"2017","journal-title":"The Lancet Oncology"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi\u2010center study of 683 patients","volume":"5","author":"Mato A.R.","year":"2017","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_14_1","first-page":"4315","article-title":"Disease and patient characteristics, patterns of care, toxicities, and outcomes of Chronic Lymphocytic Leukemia (CLL) patients treated with venetoclax: a multicenter study of 204 patients","volume":"130","author":"Mato A.R.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193615"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21595"},{"key":"e_1_2_8_18_1","first-page":"311","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"4","author":"Roberts A.W.","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_2_8_21_1","first-page":"3025","article-title":"Venetoclax (VEN) is active in Chronic Lymphocytic Leukemia (CLL) relapsed or refractory to more than one B\u2010cell receptor pathway inhibitor (BCRi)","volume":"130","author":"Wierda W.G.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_22_1","first-page":"4329","article-title":"Impact of number of prior therapies and bulk of disease on outcomes with Venetoclax (VEN) monotherapy for relapsed\/refractory Chronic Lymphocytic Leukemia (CLL)","volume":"130","author":"Wierda W.G.","year":"2017","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15802","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15802","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T20:32:30Z","timestamp":1720989150000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/bjh.15802"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15802","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"2018-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}